Stefanie Flückiger-Mangual

CEO TOLREMO therapeutics

Paving the way to improved cancer therapy

tolremo.com
tolremo-therapeutics

Main product:
Resistance-preventing Cancer Medicines

Aim:
To fight cancer drug resistance through a new approach



TOLREMO therapeutics

Start year:
2017
Generated funding:
EUR 15 000 000

Challenge:
Personalised cancer therapy

eit Awards VENTURE

Powered by:

eit Health

THE PROJECT

The idea
An increasing number of personalised therapies block the mutated proteins that drive cancer. However, many of these therapies fail due to cancer's resistance to drugs. Our new approach aims to make personalised cancer therapies even more personal and thereby longer lasting.

Inspiration
By combining classic mutational information ("the hardware of a cancer") with novel transcriptional information that defines the exact pattern of genes expressed in that particular cancer ("the software of a cancer"), we design and develop combination therapies that will prevent the development of drug resistance.

Unique selling points
We believe that our technology has the potential to disrupt the current standard of practice and we envision it as an alternative therapy that offers higher response rates, shortens the treatment window, and provides a cure to patients.

Societal impact
Transparent pricing and efficiency reduce trading costs to Despite medical advances, cancer remains a life-altering diagnosis. TOLREMO makes cancer therapies more efficient and longer lasting, resulting in longer life expectancy and better quality of life for patients and reduction in healthcare costs.

Venture development
We identified novel drug candidates and are now developing one of our drug prototypes in further preclinical testing. The next step will consist of regulatory safety and toxicity studies, the completion of a data package that supports regulatory approval, and subsequent clinical testing in humans.

EIT Community support
The EIT Health Gold Track programme has helped us devise strategies to leverage the full clinical and commercial potential of our solution. EIT Health and Gold Track connected us with C-level experts who also provided personalised support.

THE NOMINEE

The beginning
The topic of drug resistance in cancer has been close to my heart for almost 10 years now. The results of my PhD research suggested new ways to prevent resistance development from the very start of a cancer therapy. This was extraordinarily encouraging.

Rewarding moments
A most rewarding moment was when we realised that our technology had indeed identified a novel modulator of drug resistance in cancer. It was something that people had told us would not be possible – but we did it anyway!

> "It was something that people had told us would not be possible – but we did it anyway!"